201 related articles for article (PubMed ID: 31847542)
1. Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
Zhu Y; Koleck TA; Bender CM; Conley YP
Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
[TBL] [Abstract][Full Text] [Related]
2. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
3. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
Rumiato E; Brunello A; Ahcene-Djaballah S; Borgato L; Gusella M; Menon D; Pasini F; Amadori A; Saggioro D; Zagonel V
Pharmacogenomics J; 2016 Nov; 16(6):525-529. PubMed ID: 26503812
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Gallicchio L; MacDonald R; Helzlsouer KJ
J Cancer Res Clin Oncol; 2013 May; 139(5):837-43. PubMed ID: 23408333
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of aromatase inhibitors.
Hadfield KD; Newman WG
Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
[TBL] [Abstract][Full Text] [Related]
6. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
7. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
[TBL] [Abstract][Full Text] [Related]
8. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
10. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
[TBL] [Abstract][Full Text] [Related]
11. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
[TBL] [Abstract][Full Text] [Related]
13. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
14. Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.
Olufade T; Gallicchio L; MacDonald R; Helzlsouer KJ
Support Care Cancer; 2015 Feb; 23(2):447-55. PubMed ID: 25128067
[TBL] [Abstract][Full Text] [Related]
15. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
18. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study.
Martínez N; Herrera M; Frías L; Provencio M; Pérez-Carrión R; Díaz V; Morse M; Crespo MC
Clin Transl Oncol; 2019 Apr; 21(4):489-498. PubMed ID: 30293230
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
[TBL] [Abstract][Full Text] [Related]
20. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
